Investor Presentaiton
Strong business momentum
Diversified portfolio growth
Efficient compounding engine
Sustainable long-term growth
Simple and efficient business model focused on cash flow
Biopharma
Sales of leading
therapies
Funding to
partners
New royalty
acquisitions
Return of capital
(Dividends and potential
share repurchases)
Adjusted Cash(¹)
Cash generated
% of sales
Receipts
("top-line")
ROYALTY PHARMA
for deployment
Diversified portfolio
of royalties
Operating expenses
("G&A”)
Adjusted
EBITDA (1)
Interest expense
(Investment grade debt)
Large diversified royalty portfolio generates significant cash to redeploy in new royalties
ROYALTY PHARMA 1. See slide 114 for definitions. Refer to the Appendix for a GAAP to non-GAAP reconciliation.
84View entire presentation